Fractyl Health, Inc (GUTS) - Koefisien utang jangka dawa marang modal

Fractyl Health, Inc - logo grafis emiten GUTS

Fractyl Health, Inc. (GUTS) restores patient metabolism through mucosal regeneration, offering an alternative to pharmaceuticals. The long-term debt-to-equity ratio clearly demonstrates financial stability, with 0.00 representing the latest metric reading. However, the company is battling industry behemoths in an overheated niche, deploying hardware solutions to capture market share before mass-market analogs emerge.

Fractyl Health Inc. (GUTS): Utang jangka dawa marang ekuitas saka 21.02.2024 nganti 30.10.2026
Produk mawa merek Fractyl Health, Inc.

Investors are assessing the financial stability of Fractyl Health, Inc. (GUTS) through the lens of long-term liabilities. This metric determines the ratio of loans with a maturity of more than one year to total equity, measuring the level of long-term financial leverage. The long-term debt-to-equity trend allows for the monitoring of excessive borrowing risks. For a company in a post-IPO adaptation phase, this balance confirms confidence in the innovative platform. A stable indicator ensures the security of medical technology expansion.

Analisis perusahaan pesaing

Ascendis Pharma AS - Kewajiban jangka dawa marang ekuitas|Utang jangka dawa marang modal MDGL|CORT (Corcept Therapeutics Corp) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal RYTM (Rhythm Pharmaceuticals)|Utang jangka dawa marang modal akerotx.com AKRO|MTSR - Utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal MLTX (MoonLake Immunotherapeutics AG)|Crinetics Pharma (CRNX) - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang ekuitas NewAmsterdam Pharma Corp|SLNO (Soleno Therapeutics) - Utang jangka dawa marang modal|Utang jangka dawa marang modal amicusrx.com|Rasio utang jangka dawa marang ekuitas ETNB (89bio)|AGIO (Agios) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Structure Pharma GPCR|MDXG - Rasio utang jangka dawa marang ekuitas|Rezolute, Inc. - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal lexpharma.com|MBX (MBX Biosciences) - Rasio utang jangka dawa marang ekuitas|ALT: Rasio silihan jangka dawa marang modal|AARD (Aardvark Therapeutics Corp) - Utang jangka dawa marang modal|Utang jangka dawa marang modal Sagimet Biosciences Inc|Utang jangka dawa marang modal BIOA|Utang jangka dawa marang ekuitas BMEA (biomeafusion.com)|Utang jangka dawa marang ekuitas Quince Therapeutics, Inc. QNCX|vTv Therapeutics, Inc. (VTVT) - Kewajiban jangka dawa marang modal|ATPC - Utang jangka dawa marang ekuitas|PLUR: Utang jangka dawa marang ekuitas|SYBX: Utang jangka dawa marang modal|LPCN - Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Matinas BioPharma Holdings, Inc.|Spruce Biosciences Inc. (SPRB) - Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Galecto Corp (GLTO)|Rasio utang jangka dawa marang ekuitas Carmell Therapeutics CTCX|Utang jangka dawa marang modal LUMO (Lumos Pharma, Inc.)|ONVO (organovo.com) - Kewajiban jangka dawa marang ekuitas|RDUS - Utang jangka dawa marang ekuitas